These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 34737224)

  • 1. Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China.
    Zheng X; Davies Forsman L; Bao Z; Xie Y; Ning Z; Schön T; Bruchfeld J; Xu B; Alffenaar JW; Hu Y
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34737224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
    Heysell SK; Mpagama SG; Ogarkov OB; Conaway M; Ahmed S; Zhdanova S; Pholwat S; Alshaer MH; Chongolo AM; Mujaga B; Sariko M; Saba S; Rahman SMM; Uddin MKM; Suzdalnitsky A; Moiseeva E; Zorkaltseva E; Koshcheyev M; Vitko S; Mmbaga BT; Kibiki GS; Pasipanodya JG; Peloquin CA; Banu S; Houpt ER
    Clin Infect Dis; 2023 Feb; 76(3):497-505. PubMed ID: 35731948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
    Zheng X; Zheng R; Hu Y; Werngren J; Forsman LD; Mansjö M; Xu B; Hoffner S
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4786-92. PubMed ID: 27246779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis.
    Zhang H; He Y; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Alffenaar JW; Hu Y
    Front Pharmacol; 2022; 13():1032674. PubMed ID: 36699070
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.
    Davies Forsman L; Niward K; Hu Y; Zheng R; Zheng X; Ke R; Cai W; Hong C; Li Y; Gao Y; Werngren J; Paues J; Kuhlin J; Simonsson USH; Eliasson E; Alffenaar JW; Mansjö M; Hoffner S; Xu B; Schön T; Bruchfeld J
    BMJ Open; 2018 Oct; 8(9):e023899. PubMed ID: 30287613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
    Forsman LD; Jonsson J; Wagrell C; Werngren J; Mansjö M; Wijkander M; Groenheit R; Hammar U; Giske CG; Schön T; Bruchfeld J
    Clin Infect Dis; 2019 Sep; 69(8):1394-1402. PubMed ID: 30561569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis.
    Kuhlin J; Davies Forsman L; Mansjö M; Jonsson Nordvall M; Wijkander M; Wagrell C; Jonsson J; Groenheit R; Werngren J; Schön T; Bruchfeld J
    Clin Infect Dis; 2021 Nov; 73(9):e3511-e3517. PubMed ID: 33011791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing.
    Chen X; He G; Lin S; Wang S; Sun F; Chen J; Zhang W
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33361124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients.
    Shao G; Bao Z; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Alffenaar JW; Hu Y
    Front Pharmacol; 2023; 14():1022090. PubMed ID: 37050904
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
    Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study.
    Sun F; Li Y; Chen Y; Guan W; Jiang X; Wang X; Ren P; Li J; Shi J; He G; Wu M; Tang P; Wang F; Sheng Y; Huang F; Zhou Z; Huang H; Hong L; Liu Q; Zhang Y; Zhang W
    Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis.
    Zheng X; Ning Z; Drobniewski F; Yang J; Li Q; Zhang Z; Hu Y
    Int J Antimicrob Agents; 2017 Feb; 49(2):183-188. PubMed ID: 28012685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
    Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
    Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluroquinolone drug resistance among MDR-TB patients increases the risk of unfavourable interim microbiological treatment outcome: An observational study.
    Singh N; Singh PK; Singh U; Garg R; Jain A
    J Glob Antimicrob Resist; 2021 Mar; 24():40-44. PubMed ID: 33279685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.